{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:43:55Z","timestamp":1789821835712,"version":"4.0.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05955-0","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T08:38:24Z","timestamp":1759394304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inlexzo (gemcitabine intravesical system): promising data but key questions remain"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0117-8615","authenticated-orcid":false,"given":"Zarmeen","family":"Azhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7915-0320","authenticated-orcid":false,"given":"Zehra","family":"Sadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"5955_CR1","unstructured":"Food US, Administration D (2025) FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-gemcitabine-intravesical-system-non-muscle-invasive-bladder-cancer. Accessed 11 Sept 2025"},{"key":"5955_CR2","unstructured":"Janssen Media Center (2025) U.S. FDA approval of INLEXZO (gemcitabine intravesical system) set to transform treatment of certain bladder cancers. https:\/\/www.jnj.com\/media-center\/press-releases\/u-s-fda-approval-of-inlexzo-gemcitabine-intravesical-system-set-to-transform-how-certain-bladder-cancers-are-treated. Accessed 11 Sept 2025"},{"issue":"6","key":"5955_CR3","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","volume":"25","author":"A Necchi","year":"2024","unstructured":"Necchi A, Verri C, Zaffaroni N, Carrega P, Giannatempo P, Soria F, Shariat SF, Di Trapani E, Rosenquist J, Lucchesi M et al (2024) Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma-in-situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol 25(6):720\u2013730. https:\/\/doi.org\/10.1016\/S1470-2045(24)00178-5","journal-title":"Lancet Oncol"},{"key":"5955_CR4","unstructured":"OncLive (2025) FDA approves TAR-200 in BCG-unresponsive NMIBC with CIS. https:\/\/www.onclive.com\/view\/fda-approves-tar-200-in-bcg-unresponsive-nmibc-with-cis. Accessed 11 Sept 2025"},{"key":"5955_CR5","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.eururo.2009.01.006","volume":"55","author":"S Gudj\u00f3nsson","year":"2009","unstructured":"Gudj\u00f3nsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T, Richthoff J, Hagberg G, Grabe M, Bendahl PO, M\u00e5nsson W, Liedberg F (2009) Should all patients with non\u2013muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 55:773\u2013780. https:\/\/doi.org\/10.1016\/j.eururo.2009.01.006","journal-title":"Eur Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05955-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05955-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05955-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:02:12Z","timestamp":1767999732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05955-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5955"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05955-0","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"586"}}